MDRNA Announces Licensing Agreement with Roche
News Feb 16, 2009
MDRNA, Inc. announced that it has entered into an agreement with Roche in which Roche will obtain a non-exclusive license to a portion of MDRNA's technology platform for the development of RNAi-based therapeutics. Terms of the agreement were not disclosed.
"We are pleased to have Roche recognize the value of our drug discovery platform," stated J. Michael French, President and Chief Executive Officer of MDRNA.
"To have a portion of our platform in-licensed by Roche, a company with a significant effort in RNAi-based therapeutics, is a great testament to our intellectual property estate as well as the strong science being performed by our researchers. This agreement provides us the necessary resources to continue to pursue multiple, non-exclusive research collaborations, as well as future financing opportunities. We look forward to working with Roche to capitalize on the platform capability we are licensing to them as part of this agreement."
The Ancient Behaviour of Sleep, Conserved Throughout EvolutionNews
The finding that jellyfish sleep implies that sleep is an ancient behavior, largely untouched by millennia of evolution.READ MORE
Gene Immunotherapy Approach Prevents and Reverses Symptoms of Multiple SclerosisNews
Researchers used a viral vector to deliver a gene encoding a myelin sheath protein to the liver, thereby inducing robust and durable immune tolerance in mice by preventing T cells from attacking the myelin sheath.READ MORE
Genetic Code of Neuronal Communication Determines Cell TypeNews
The findings should help scientists sort out the bewildering array of neurons that are intertwined in the brain.READ MORE